Find an expert

Professor Fairlie is an NHMRC Research Investigator Fellow (Level 3) (2022-present), a Node Leader of the ARC Centre of Excellence for Innovations in Peptide Protein Science, one of four Centre Directors and former Head of the Division of Chemistry of Structural Biology at the Institute for Molecular Bioscience (since 2009), and an Affiliate Professor of the School of Chemistry and Molecular Biosciences. He was previously an NHMRC Senior Principal Research Fellow (2012-2021), a Node Leader at the ARC Centre of Excellence in Advanced Molecular Imaging (2014-2021), an ARC Federation Fellow (2006-2011), an ARC Professorial Fellow (2002-2006), and Scientific Director and Chief Scientific Officer of a startup company. He undertook postdoctoral studies at Stanford University and University of Toronto, postgraduate studies at Australian National University and University of New South Wales, and undergraduate studies at University of Adelaide.

His research group works across the disciplines of chemistry (synthesis, structure, reaction mechanisms), biochemistry (enzyme inhibitors, protein-protein interactions, GPCRs, transcription factors), immunology (innate immune cells in health and disease, mucosal T cells), and pharmacology (molecular pharmacology and human cell signalling, experimental pharmacology in rodent models of human diseases). He has published over 480 scientific journal articles in high impact chemistry journals (e.g. Chem Rev, Acc Chem Res, J Am Chem Soc, Angew Chem Int Edit, Chem Sci, J Med Chem, Org Lett, J Org Chem) and biology journals (e.g. Nature, Science, Nat Rev Endocrinol, Mol Cancer, Immunity, Nature Immunology, Science Immunology, Am J Resp Crit Care Med, J Hepatol, Trends Immunol, Mol Neurodegen, Adv Drug Deliv Rev, Nature Communications, Trends Pharmacol Sci, J Exp Med, J Clin Invest, Kidney Int, Arthritis & Rheum, Science Advances, Pharmacol Ther, Cancer Res, Proc Natl Acad Sci USA, Dev Cell, Curr Biol, J Cell Biol, Cell Reports, PloS Biol, Br J Pharmacol, JCI Insight, Diabetes, Mucosal Immunol, etc). He has been a Highly Cited Researcher (Clarivate Analytics), with over 37,000 citations and 113 publications with over 100 citations (Google Scholar), and has collaborated with many of the world’s largest pharmaceutical and biotechnology companies.

Jad is a postdoctoral research fellow at the Frazer Institute, currently focused on the detailed immune profiling of novel group A Streptococcus vaccines, with a specific interest in dissecting the diverse immune responses generated by StrepA vaccines. His expertise is built upon a PhD in cancer immunotherapy and immunology, where he investigated the role of complement receptors in glioblastoma (GBM) tumour growth. Jad possesses strong technical proficiency in working with murine models and advanced multi-colour flow cytometry (capable of +40 colours). Furthermore, his commitment to education is recognized through a fellowship in the Higher Education Academy.

Dr Fernando's current research interests include developing needle-free, pain-free, skin patch vaccines. Influenza and human papilloma virus vaccines are used as model vaccines in these studies.

Dr Germain Fernando completed PhD at the University of Arizona, USA, and did post-doctoral research at the Baylor College of Medicine, Houston, Texas, USA, before joining the University of Queensland in 1989. He has been working in the field of vaccinology for the last 28 years. He has a H-Index of 36.

He is a Senior Consultant at Vaxxas Pty. Ltd, Brisbane, Australia

Publications and Citation Metrics are available at the following website:

http://www.researcherid.com/rid/C-3733-2009

Professor Ian Frazer is a clinician scientist, trained as a clinical immunologist in Scotland. As a professor at the University of Queensland, he leads a research group working at TRI in Brisbane, Australia on the immunobiology of epithelial cancers. He is recognised as co-inventor of the technology enabling the HPV vaccines, currently used worldwide to help prevent cervical cancer. He heads a biotechnology company, Jingang Medicine (Aus) Pty Ltd, working on new vaccine technologies, and is a board member of several companies and not for profit organisations. He was the inaugural president of the Australian Academy of Health and Medical Sciences, and a member of the Australian National Science and Technology Council. He chairs the Australian Medical Research Advisory Board of the Medical Research Future Fund.

He was recognised as Australian of the Year in 2006. He was recipient of the Prime Ministers Prize for Science, and of the Balzan Prize, in 2008, and was elected Fellow of the Royal Society of London in 2012. He was appointed Companion of the Order of Australia in the Queen’s Birthday Honours list in 2013.

Dr Jenny Fung is a Senior Research Officer in the School of Biomedical Sciences (SBMS). Her research focuses on understanding how multi-omics—including genomics, transcriptomics, and proteomics—and immune mechanisms contribute to complex diseases, with the aim of translating laboratory discoveries into improved patient outcomes.

Dr Fung completed her PhD in Endocrinology at The University of Queensland and undertook postdoctoral training at QIMR Berghofer and the Institute for Molecular Bioscience (IMB, UQ) in Professor Grant Montgomery’s laboratory. There, she used high-throughput genetic and genomic approaches to uncover key molecular mechanisms underlying endometriosis. In 2019, she joined Professor Trent Woodruff’s laboratory, where she expanded her research to neurodegenerative diseases, including motor neuron disease (MND), Huntington’s disease (HD), and frontotemporal dementia (FTD). Her work spans both preclinical and patient-focused studies, including contributions to a Phase Ib clinical trial in MND, the identification of immune and molecular biomarkers in longitudinal patient cohorts, and the evaluation of therapeutic targets using patient-derived cells.

Dr Fung has published over 40 peer-reviewed papers in journals including Nature Genetics, Nature Communications, PNAS, and Brain, Behavior, and Immunity. She is passionate about connecting laboratory discoveries with clinical impact and co-leads projects integrating multi-omics, immunology, and patient-focused research to develop new strategies for treating complex diseases.

Dr Kate Gartlan is an immunologist with considerable expertise in cellular immunology, particularly using in vivo models of inflammation to investigate immune-modulation and T cell polarisation. Dr Gartlan began her research career at WEHI within Professor Ken Shortman’s laboratory developing strong skills in both molecular and cell biology, where she became interested in the early factors that influence adaptive immunity. She completed her PhD in 2009 at the Burnet Institute working with Associate Professor Mark Wright, where she studied functional redundancy between Tetraspanin proteins in the immune system. To advance her understanding of inflammatory mediators and adaptive immune polarisation, she moved to the University of Oxford and took up a postdoctoral position within the Sir William Dunn School of Pathology. Working with Professor Quentin Sattentau, she investigated novel ways to modulate T cell polarisation and influence B cell responses to HIV vaccines.

After returning to Australia, she has worked with Professor Geoff Hill at QIMR Berghofer investigating novel therapies to treat graft-versus-host disease (GVHD) in allograft recipients. Dr Gartlan has held active teaching roles within both university and research institute environments, contributing to undergraduate science and medicine programs at both departmental and college levels.

Her main research interests at present surround the role of IL-17 & IL-22 in GVHD, potential therapeutics to modulate T cell polarisation after allogeneic bone marrow/stem cell transplant (BMT/SCT), as well as developing novel inhibitors of graft rejection to improve engraftment after BMT/SCT.

Dr Christian Gray is a Senior Lecturer in Medical Education (Personalised Learning & USMLE Prep) at The University of Queensland Medical School. His work focuses on personalised learning, assessment and preparation for medical licensing examinations, with a particular interest in understanding how individual students learn, prepare and adapt.

Dr Gray joined UQ in 2019, having previously been a Lecturer in Infection and Immunity and Immunology Discipline Lead at Peninsula Medical School, University of Plymouth, UK. He holds a PhD from the University of Newcastle, Australia, and a Postgraduate Diploma in Academic Practice from the University of Plymouth, and is a Fellow of the Higher Education Academy.

Prior to moving into medical education, Dr Gray undertook postdoctoral research across a range of areas in immunology, including tumour immunology, rheumatoid arthritis, pneumococcal immunity, mastitis resistance in dairy cattle and vaccine development. His biomedical research has been published in journals including Blood, Cancer Research, The Journal of Immunology, Clinical Cancer Research and Mucosal Immunology.

At UQ, Dr Gray's scholarship focuses on how students prepare for high-stakes assessment and medical licensing examinations and how assessment and learning data can be used to understand student readiness and learning behaviour. Within the UQ-Ochsner medical program, he has developed and coordinated structured preparation for USMLE Step 1. His research includes longitudinal investigation of student preparation and question-bank engagement, including changes associated with the transition of USMLE Step 1 to pass/fail reporting.

His work in medical licensing assessment extends internationally. He has contributed chapters to Cambridge University Press texts providing guidance for students preparing for and taking the UK Medical Licensing Assessment Applied Knowledge Test (MLA AKT). His broader educational scholarship includes personalised learning, support for students experiencing academic difficulty, inclusive approaches to learning and assessment, and understanding how learners adapt their preparation in response to assessment.

More broadly, Dr Gray's research interests extend to learning and learning behaviour across higher education, including the emerging role of artificial intelligence and its relationship with cognitive and non-cognitive aspects of learning. He currently supervises doctoral research in this area.

Judith Greer is an immunologist with a strong interest in the nervous system and autoimmune diseases affecting the nervous system.

She is a graduate of the University of Queensland, having completed her PhD on cancer immunology. She then undertook postdoctoral training at Harvard Medical School in the USA, during which time her interests shifted towards immune responses and interactions within the nervous system (neuroimmunology), an area in which she has worked ever since. She isa Principal Research Fellow at the UQ Centre for Clinical Research, located at the Royal Brisbane & Women's Hospital.

Her research is directly particularly towards trying to identify brain components that are targetted by the immune system in people with a variety of disorders, particularly multiple sclerosis (MS), which is traditionally thought to be an autoimmune disease, but also in psychosis, where we are now starting to understand that autoimmune targetting of the brain can play a role in some patients. She is interested in how the specificity of autoimmune responses within the nervous system relates to the symptoms experienced by patients, and in developing new ways to specifically turn off the damaging immune responses in the brain. Another focus of her research is to improve on pre-clinical models of MS, so as to enhance the translation of new therapeutic approaches for MS to the clinic.

Judith is also interested in research training, and held leadership positions in this area in the School of Medicine and the Faculty of Medicine at UQ from 2000 - 2023. She is also committed to improving the field of neuroimmunology, and has been a member of the International Advisory Board of the International Society for Neuroimmunology and is the Asia-Pacific representative for the Global Schools of Neuroimmunology. Judith co-founded a society, Neuroimmunology Australia, to better support those working in this field, and was Convenor and Chair of the 14th International Congress of Neuroimmunology, which was held in Brisbane in 2018 (the only time this congress has been held outside of the Northern Hemisphere).

Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.

As Director of IMPACT (Immunocellular Manufacturing Platform for Advanced Cell Therapies), a MRFF-NCRI initiative, I lead a research program with extensive expertise in immunology, particularly in natural killer (NK) cells, focused on developing innovative approaches for treating hard-to-cure diseases like metastatic cancers. Our mission is to improve patient outcomes and extend lives. Recognized as an international leader in my field, I've been instrumental in identifying novel regulators of our immune functions, and developing NK cell-based immunotherapies.

My dedication to my field has been recognized through numerous peer-reviewed grants as sole-CI or CIA/Principal Investigator, including a NHMRC ECF Peter Doherty Fellowship, an NHMRC Project Grant, a US DoD grant, and a MRFF EMCR, among others. Since 2009, I've amassed a portfolio of >130 publications in renowned journals like JEM, Molecular Therapy, Nat Comms, and Nat Immunol. My body of work and contributions have been acknowledged with awards such as the 2019 Researcher of the Year by Cure Cancer Australia, 2020 QLD Young Tall Poppy Science, 2020 UQ Frazer Institute's Rising Star, 2022 Frazer Institute's Mentor of the Year, 2023 TRI – Connecting with the Clinic, and the 2025 Dr. Jian Zhou Foundation Award for Translational Medicine, among others. In addition, I currently serve as Deputy Editor of Immunology and Cell Biology.

Since 2024 I have served as Chair of Research and Non-Executive Director of Cure Cancer Australia, the national peak body for early- and mid-career cancer research funding, where I chair the research committee and oversee grant assessment panels. I also Co-Chair the Frazer Institute's Industry Engagement and Commercialisation Committee, shaping the Institute's approach to IP management, spin-out governance, and industry partnerships. Committed to translating fundamental discoveries into real-world therapies, I co-founded the venture-backed biotechnology company Sicario Tx, focused on advancing NK cell-based immunotherapies. I have also served as a scientific consultant and collaborator for national and international biotech companies, including Biotheus (now part of BioNTech's oncology pipeline), Prescient Therapeutics, and Microba Life Sciences, contributing to their development programs.

At present, I am a Group Leader / Principal Research Fellow & Associate Professor with the University of Queensland's Frazer Institute, where I direct IMPACT — UQ's cell therapy manufacturing and translational platform, operating as an academic CRO for academic and industry partners, from cell engineering and manufacturing through to trial-enabling preclinical studies. My research group is based at the Translational Research Institute (TRI). Here, I lead a high-performing research team with a keen focus on developing and innovating immunotherapy approaches for a spectrum of diseases.

Professor Emma Hamilton-Williams’ career focuses on understanding how immune tolerance is disrupted leading to the development of the autoimmune disease type 1 diabetes. She received her PhD from the Australian National University in 2001, followed by postdoctoral training in Germany and the Scripps Research Institute in the USA.

In 2012, she started a laboratory at the Frazer Institute, University of Queensland where she investigates the gut microbiota as a potential trigger or therapy target for type 1 diabetes, as well as developing an immunotherapy for type 1 diabetes. The overall aim of her research is to find new ways to prevent or treat the underlying immune dysfunction causing autoimmunity.

She is Chief Scientific Officer for an Australia-wide pregnancy-birth cohort study of children at increased risk of type 1 diabetes, which aims to uncover the environmental drivers of this disease. Her laboratory uses big-data approaches including proteomics, metabolomics and metagenomics to understand the function of the gut microbiota linked to disease.

She recently conducted a clinical trial of a microbiome-targeting biotherapy aimed at restoring a healthy microbiome and immune tolerance, with an ultimate aim of preventing type 1 diabetes.

I am a Research Fellow and Leader in Pain Relief Innovation at AIBN, UQ. My research interests sit at the interface of drug delivery and the pain field. My overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management. I am looking for highly motivated postgraduate students.

I also enjoy volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). I am currently serving as guest editor of Pain Research and Management.and JoVE Methods Collection.

Research Interests

My research is focusing on nano-based drug formulation and development to improve chronic pain management. I have a broad and unique background in both pharmacology and drug delivery systems, with specific expertise in the development of novel drug products and testing their analgesic efficacy and safety including pharmacokinetic and pharmacodynamic studies. To date, I have established five different techniques to produce painkiller–loaded nanoparticles and nanofibers aimed at improving pain relief for patients where currently available pain-killers either lack efficacy or produce dose-limiting side-effects. For example, there is a small and very potent peptide that has been on the market as a chemical for over 10 years but which cannot be used as a therapeutic due to its short half-life and poor oral bioavailability. In the form of my nanoparticles, that peptide has the potential to become an oral treatment for improving pain management in patients whose pain is currently poorly alleviated by clinically used pain-killers. I have significant expertise in the use of rodent pain models to assess novel analgesics, and I have received excellent training in conducting research in accordance with the stringent requirements of the Quality Management System (quality accreditations (GLP and ISO17025) from NATA). Together, my knowledge, skills and experience will facilitate the efficient translation of my research from the bench to the clinic.

The current focus of the lab is on the development of drug-products to solve one of the largest unmet medical needs in the pain field through use of sustainable materials. 1) We are developing multifunctional sutures including biodegradable pain relief sutures. 2) We are developing my innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. We are establishing a platform for the development of safe, effective delivery for other small molecule peptide drugs in general to pave their way to clinical trials. 3) Our research also investigates the role of C5a and C3a, estrogen, etc. in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain and OA pain.

We work in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. We also provide preclinical evaluation of novel compounds and formulations.

The research interests of the Hume Laboratory centre on the biology of macrophages and osteoclasts. These are cells of haematopoietic origin that are closely related to each other but have distinctly different activities.

David Hume was a group leader at the Institute for Molecular Bioscience (1988-2007) and subsequently Director of the Roslin Institute at the University of Edinburgh in Scotland from 2007-2017. He is currently a Professorial Research Fellow at the Mater Research Institute-UQ, located at the Translational Research Institute

Dr Snehlata Kumari is a group leader and the head of the Skin Inflammation and Immunity Laboratory at the Frazer Institute, University of Queensland, in Brisbane, Australia. Her international career and academic training spanned Germany, India, and Australia. She is a board member of the Australasian Society for Dermatology Research (ASDR) and a councillor on the International Psoriasis Council.

She has discovered novel signalling mechanisms that regulate the balance between homeostasis and inflammation in the skin. These findings highlight new mechanisms by which inflammatory diseases are initiated and propagated via NF-κB, TNF, IL-20 family cytokines, and necroptotic and apoptotic signalling pathways. Her research work has been published in top-tier journals, including Nature (3x), Nature Communications, Cell Metabolism, and Immunity.

Her scientific contributions have received international recognitions and honours, including the German National Academy of Sciences, the German Research Foundation (DFG), the European Society for Dermatological Research, the Japanese Society for Investigative Dermatology, and the Young Women Investigators Award from the International Cytokine and Interferon Society.

Overall aims and research focus

- Immunomodulatory mechanisms regulating inflammation and immunity.

- Cellular and cell-soluble factor interactions in inflammatory diseases, including Psoriasis, Hidradenitis Suppurative, and Atopic Dermatitis.

Dr Larisa Labzin is an ARC Future Fellow and leads the viruses and innate immunity lab at the Institute for Molecular Bioscience. Her lab studies how our innate immune system detects viral infections and deciphers diverse signals to mount an appropriate immune response, with a focus on influenza and SARS-CoV-2. The Labzin group aims to identify new therapeutic targets to prevent and treat viral infections and diseases in humans and animals.

The lab has four key research areas: (1) how viral tropism and life cycle shape innate immune sensing and inflammation; (2) how pre-existing antibodies influence innate responses to viruses and vaccines; (3) how innate immune signalling differs across patient risk groups and species; and (4) how viral-triggered inflammation drives vascular dysfunction and thrombosis. As cell biologists, the Labzin Lab studies the primary cellular targets of these viruses (respiratory epithelial cells, macrophages, and endothelial cells) using imaging, molecular biology, gene editing, and immunological approaches.

Dr Labzin started her career in innate immunity with Honours at the Institute for Molecular Bioscience (IMB) at UQ with Prof. Matt Sweet before relocating to Germany to undertake her PhD with Prof. Eicke Latz, a world leader in innate immunity (2015, University of Bonn). She was subsequently awarded an EMBO Fellowship and NHMRC CJ Martin Fellowship to undertake postdoctoral training at the MRC-Laboratory of Molecular Biology in Cambridge, UK, from 2016 to 2019. She returned to Australia in 2019 as a CJ Martin Fellow to start her independent research team at the IMB under the mentorship of Prof. Kate Schroder. She was heavily involved in science communication during the COVID-19pandemic and was a 2022 QLD Tall Poppy recipient and winner of the 2022 Australian Society of Immunology Public Engagement Award.

Dr John Lee is the Ross Maclean Senior Research Fellow and a Group Leader at the Queensland Brain Institute (QBI). He holds a joint appointment at UQ’s School of Biomedical Sciences. A mid-career researcher with training in neuroscience, pharmacology, and inflammatory pathways, including the complement system and inflammasomes in motor neuron disease (MND), Huntington’s disease, and Parkinson’s disease.

Dr. Lee completed his PhD at UQ in 2014, before pursuing postdoctoral research in neuroinflammation and neurodegeneration. His translational studies have demonstrated the therapeutic potential of anti-inflammatory compounds to reduce neuronal cell death in animal models, with one candidate advancing to Phase 1B clinical trials. He is also collaborating on novel liquid drug formulations to meet the needs of MND patients who lose the ability to swallow.

Supported by the Ross Maclean Fellowship, which was established in memory of Ross Maclean, who lost his battle with MND in 2005, Dr Lee is working to accelerate drug programs towards the clinic and improve the quality of life for people living with MND.

Dr Odette Leiter is a postdoctoral research fellow in the research group of Dr Tara Walker, investigating systemic brain rejuvenation. She was awarded a PhD in Neuroscience in 2018 by the Technische Universität Dresden in Germany. Her research focus lies on the regulation of adult hippocampal neurogenesis by physical exercise, a process critically involved in learning and memory.

To support her research at the Queensland Brain Institute, Dr Odette Leiter has received two postdoctoral fellowships, a postdoctoral fellowship from the German Academic Exchange Service, followed by a Walter Benjamin Fellowship awarded by the German Research Foundation, allowing her to investigate the role of platelets in mediating neurogenesis-related learning and memory, and the capacity of platelet-released factors to restore cognitive function in ageing. More recently, Dr Leiter has been awarded a Discovery Early Career Researcher Award (DECRA) to investigate the precise mechanisms through which platelets interact with adult hippocampal neural stem cells following exercise.